摘要目的 探讨口服布洛芬治疗早产儿动脉导管未闭(PDA)的疗效以及安全性,同时研究相关因素对疗效影响.方法 符合入选标准的PDA患儿53例给予口服布洛芬治疗,观察患儿动脉导管关闭情况以及不良反应.结果 本组首次治疗有效率为84.91%,治疗失败者8例,经第2疗程治疗后有2例PDA关闭,因此,PDA关闭总有效率为88.68%.研究表明布洛芬的用药时间和患儿出生体重对PDA关闭率均有积极显著的影响,且无严重不良反应发生.结论 布洛芬治疗早产儿动脉导管未闭疗效确切,用药安全.早期应用布洛芬,可显著提高早产儿的PDA关闭率.

abstractsObjective To explore the efficacy and safety of ibuprofen in patent ductus arteriosus (PDA) treatment in premature infants, and investigate correlation factors that effected the efficacy. Methods 53 cases of PDA that matched the selected standards were treated with ibuprofen orally. The closure of ductus arteriosus and adverse reactions were under observation. Results Effective power of first treatment in our research was 84. 91% ,8 cases failed. Two cases of PDA were closed after the second course of treatment. The total effective rate was 88.68%. This research also indicated that the time to use ibuprofen and the birth weight of children were of positive and notable effect on closure rate of PDA. No serious adverse reaction occurred during the research. Conclusion Ibuprofen in PDA treatment is safe and of certain efficacy. It can obviously elevate the rate of PDA closure in premature infants to use ibuprofen early.